LC/MS/MS Bioanalytical Methods
Pyxant Labs specializes in rapid method development and validation of proprietary methods for our life sciences clients. We emphasize extensive refinement at the development stage,resulting in the most rugged and precise assays. Pyxant Labs also offers validated LC/MS/MS bioanalytical methods which are non-proprietary to our clients. If your project requires support beyond the methods listed here, please contact John Begley, Director of Operations, at jbegley@pyxant.com or at 719-593-1165 x33.
| Bioanalytical Method | Matrix | Method Range | Sample Volume |
| Acetaminophen | Human Plasma | 250 to 10,000 ng/mL | 25 µL |
| Amlodipine (In Development) | Human Plasma | 0.1 to 100 ng/mL | 200 µL |
| Budesonide | Human Plasma | 10.0 to 750 pg/mL | 150 µL |
| Candesartan (In Development) | Human Plasma | 0.5 to 500 ng/mL | 200 µL |
| Capsaicin | Human Plasma | 0.05 to 50 ng/mL | 100 µL |
| Cicletanine (In Development) | Human Plasma | 1 to 500 ng/mL | 200 µL |
| Ciprofloxacin (In Development) | Human Plasma | 1 to 500 ng/mL | 200 µL |
| Cortisol and 6B-Hydroxycortisol (In Development) | Human Urine | 1 to 500 ng/mL | 200 µL |
| Dextromethorphan | Human Plasma | 1 to 500 ng/mL | 50 µL |
| Dextromethorphan | Human Urine | 1 to 500 ng/mL | 50 µL |
| Dextrorphan | Human Plasma | 1 to 500 ng/mL | 50 µL |
| Dextrorphan | Human Urine | 1 to 500 ng/mL | 50 µL |
| Diclofenac | Beagle Plasma | 1 to 1000 ng/mL | 150 µL |
| Digoxin (In Development) | Human Plasma | 1 to 500 ng/mL | 200 µL |
| Dipyridamole (In Development) | Human Plasma | 1 to 500 ng/mL | 200 µL |
| Fluoxetine | Human Plasma | 0.1 to 50 ng/mL | 150 µL |
| NorFluoxetine | Human Plasma | 0.1 to 50 ng/mL | 150 µL |
| Glyburide | Human Plasma | 2 to 2,000 ng/mL | 50 µL |
| Granisetron | Human Plasma | 0.05 to 50 ng/mL | 200 µL |
| Granisetron | Beagle Plasma | 0.05 to 50 ng/mL | 100 µL |
| Granisetron | Pig Plasma | 0.05 to 50 ng/mL | 100 µL |
| Hydrochlorothiazide | Human Plasma | 1 to 250 ng/mL | 300 µL |
| Hyrocodone | Human Plasma | 0.75 to 50 ng/mL | 100 µL |
| Indomethacin | Beagle Plasma | 1 to 1000 ng/mL | 150 µL |
| Methotrexate (In Development) | Human Plasma | 1 to 200 ng/mL | 200 µL |
| Moxifloxacin | Human Plasma | 25.0 to 5,000 ng/mL | 50 µL |
| Olanzapine | Beagle Plasma | 0.1 to 50 ng/mL | 100 µL |
| Phenytoin | Human Plasma | 50 to 5,000 ng/mL | 250 µL |
| Scopolamine | Human Plasma | 0.002 to 2 ng/mL | 300 µL |
| Sildenafil and N-desmethyl sildenafil | Human Plasma | 0.500 to 500 ng/mL | 50 µL |
| Tadalafil (In Development) | Human Plasma | 1 to 500 ng/mL | 200 µL |
| Telmisartan | Human Plasma | 0.5 to 5,000 ng/mL | 25 µL |
| Triamcinolone Acetate (In Development) | Human Plasma | 1 to 500 ng/mL | 200 µL |
| Valdecoxib | Human Plasma | 0.3 to 300 ng/mL | 500 µL |
| Valproic Acid | Human Serum | 1 to 100 mg/mL | 50 µL |
| Vardenafil (In Development) | Human Plasma | 1 to 500 ng/mL | 200 µL |
| R-Warfarin (In Development) | Human Plasma | 10 to 2500 ng/mL | 100 µL |
| S-Warfarin (In Development) | Human Plasma | 10 to 2500 ng/mL | 100 µL |